Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block.

Launched by KASR EL AINI HOSPITAL · Jul 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how two medications, dexmedetomidine and nalbuphine, can enhance pain relief when used with a local anesthetic called bupivacaine during neck surgeries known as anterior cervical discectomy and fusion (ACDF). These surgeries are common but can cause significant pain afterward, which can slow down recovery. The researchers want to see if adding these medications can help patients feel more comfortable and reduce the need for stronger painkillers.

To participate in the study, individuals must be between the ages of 21 and 60 and be in good health, classified as ASA I or II. This means they should have no serious health issues that could complicate the surgery. However, people with certain conditions, such as allergies to the medications used in the study, infections at the surgery site, or significant heart problems, will not be eligible. The trial is not yet recruiting patients, but once it begins, participants can expect to receive detailed information about the study and its procedures, and they will be closely monitored throughout their time in the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Physical status ASA I and ASA ll.
• • Both males and females
• • Age 21- 60 years.
• • Patients undergoing elective anterior cervical discectomy and fusion for 1 or 2 levels.
• Exclusion Criteria:
• • Patient refusal.
• • Patients undergoing anterior cervical vertebrectomy and reconstruction.
• • Patients with a history of allergy to local anesthetics or any used drugs in study.
• • Infection at the site of the block.
• • Patients with multiple cervical spine traumas.
• • Patients having surgery for malignant tumors.
• • Pre-existing peripheral neuropathies.
• • Pregnant female.
• • Patients with uncontrolled hypertension or cardiac problems as (heart block, sick sinus syndrome and ischemic heart disease).
• • Patients with coagulopathy (INR\>1.5).
• • Patients with failed block.